US 12,390,462 B2
Muscarinic acetylcholine M1 receptor antagonists
Yifeng Xiong, San Diego, CA (US); Jeffrey Roppe, Temecula, CA (US); Austin Chih-Yu Chen, San Diego, CA (US); Yalda Bravo, San Diego, CA (US); Thomas Schrader, San Diego, CA (US); and Jill Melissa Baccei, San Diego, CA (US)
Assigned to Contineum Therapeutics, Inc., San Diego, CA (US)
Filed by Contineum Therapeutics, Inc., San Diego, CA (US)
Filed on Jul. 25, 2023, as Appl. No. 18/225,992.
Application 18/225,992 is a division of application No. 17/103,455, filed on Nov. 24, 2020, granted, now 11,752,149.
Claims priority of provisional application 62/942,665, filed on Dec. 2, 2019.
Prior Publication US 2023/0364082 A1, Nov. 16, 2023
Int. Cl. A61K 31/4995 (2006.01); A61K 31/501 (2006.01); A61K 45/06 (2006.01); C07D 487/08 (2006.01)
CPC A61K 31/4995 (2013.01) [A61K 31/501 (2013.01); A61K 45/06 (2013.01); C07D 487/08 (2013.01)] 6 Claims
 
1. A method of treating multiple sclerosis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.